TERNS PHARMACEUTICALS INC. - COMMON STOCK

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

02 Jan 2025 16:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Announces Positive Early Data from Phase 1 CARDINAL Trial of TERN-701 for Chronic Myeloid Leukemia

03 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

02 Dec 2024 16:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors

18 Nov 2024 16:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Third Quarter 2024 Financial Results and Corporate Updates

12 Nov 2024 16:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals to Participate in Upcoming November Investor Conferences

06 Nov 2024 16:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

07 Oct 2024 16:05:00 By Nasdaq GlobeNewswire

Terns Announces Closing of Public Offering of Shares of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

12 Sep 2024 19:00:00 By Nasdaq GlobeNewswire

Terns Announces Pricing of Upsized $150.15 Million Public Offering

10 Sep 2024 22:50:00 By Nasdaq GlobeNewswire

Terns Announces Proposed Public Offering

09 Sep 2024 16:01:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity

09 Sep 2024 07:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Second Quarter 2024 Financial Results and Corporate Updates

05 Aug 2024 16:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

01 Aug 2024 16:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Appoints Biotech Executive Elona Kogan as Chief Legal Officer and Announces Upcoming CFO Transition

29 Jul 2024 16:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Highlights New Preclinical Data Supporting TERN-501 in Combination with a GLP-1R Agonist for Obesity at the ADA’s 84th Annual Scientific Sessions and Upcoming Conference Participation

21 Jun 2024 18:30:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

03 Jun 2024 16:10:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences

30 May 2024 08:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals to Participate in UBS Obesity Therapeutics Day

17 May 2024 16:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Updates

13 May 2024 08:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Announces Leadership Changes

08 May 2024 16:05:01 By Nasdaq GlobeNewswire